CIN No.: L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail : concorddrugs/td@gmail.com Website : www.concorddrugs.in

To,

Date: 30.05.2022

BSE Limited, P.J. Towers, Dalal Street, Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2022

Ref: Our Company's letter dated 16.05.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 30.05.2022 at 4:00 p.m. at the registered office of the company the following were considered and approved:


- 1. Audited financial results for the quarter and year ended 31.03.2022. (Enclosed)
- Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2022. (Enclosed)

The meeting concluded at 08.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely, For Concord Drugs Limited



S. Nagi Reddy Chairman & Whole time Director DIN: 01764665

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

	STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS	FOR THE LOUGH	CV FINDER 3131	March 2022		
				onverse		[Rs. in Lake
	4					
			Guarteriy ended	the second se	Year	ended
articul	ars .	31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-2
1	Revenue from Operations	(Audited)	(unAudited)	(Audited)	(Audited)	[Audited
	a. Net sales from Operations					
	b. Other Operating Income	1,546.46	1,344,17	834.63	5,895.648	3,135;
11	Other Income	2.30	2.77	2.152	10.08	G.
111	Total Revenue (1+11)	1,548,82	1,346.93	B36.78	5,905.73	
IV.	Expenses	11340.04	4,479,93	0.50.70	97409113	5,145.3
	a Cost of Material Consumed	1.065.71	1.065.86	\$\$2,782	1.1.1.1.1.1.1	10576
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-193.07	15.75		4,441.147	+,0+9.
	c Employees Benefit Expenses	160.10	120.30	42,560	251.057	168,0
	d. Pinance Crists	23.45	120.50	92.290	489.099	375
	e. Depreciation and Amortisation expense			27.486	168.075	142
	f. Other expenses	37,10	29.51	33.223	176,451	136
	Total Expenses	447.99	39.39	74.356	637.210	220.
	Profit/ (Loss) before Exceptional Item and tax (III-IV)	1,541.29	1,289.12	822.70	5,688.92	5,092.2
v	Exceptional Items	7.53	57.82	14.087	224.81	52.8
11	Profit/ (Loss) before tax (V-VI)		1920-12	23.981		376.3
VII	Tax Expense:	7.53	57.82	38.068	224.905	429.3
VIII	a. Current tax	+.00	15.68	4.501	65.37	101.0
0	b. Defenred tax charge/credit	5.14	9.56	0.155	67.12	473
IX	Profit/ (Loss) for the period (VII-VIII)	0.24	\$12	4,346	3.75	53.9
x	Other Comprehensive Income	2.73	42.14	33.567	159.43	328.1
· *	A STATE OF A STATE AND A STATE OF A	+ 2		-	-	0.000
	Berns that will not be reclassified to profit or loss					1.1
	Total Comprehensive Income for the period (comprising profit and other	2.75			1000	
XI	comprehensive income for the period) (IX+X)	- 4.7.8	42.14	33.567	159.435	328.1
AI	Pald-up equity share capital	874.38	874.38	874.38	874.38	874.3
	(Face value of the share- Rs. 10 rach)					
	Other Equity	1.961.68	1,958.95	1,802.249	1.961.65	1.802.24
XII	Earnings per share (of Rs. 10 each)		1.	1.1.1.1.1.1.1.1		1000
KIII.	a Basic (in Rs)	0.03	0.48	0.38	1.82	3.7
	b. Olluted (in Rx)	0.03	0.40	0.38	1.87	37
				N AN	8,994	3,7
otes:						
1	The finnacial results of the company hav been propared in accordance with the Indian Act 2013, road with the relevant rules issued there under.	counting Standar	th (Ind AS) press	ribed under sec	tion 133 of the C	ompanies Ad
2	The above standatone financial results as reviewd by the oudit committee have been appr	oved by Board o	f Directors at its	meeting held or	30th May ,2023	1
з	Figures of the corresponding previous periods are regrouped and reclassified wherever co	onsidered necess	ary to correspon	d with current p	eriad's presentin	ion.
4	The results are also available on the webaste of the Company www.concorddrugs.in	10	oruge			
	yderabad Ith May, 2022	Conco)E	y Order of the B or Concord Dru 5 - کوم کاری Anaging Directs	gs Limited	

.

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahma Audited Balance shi	enapally Village Hay eet as at 31st March	sthriagar Mandal RR Dist 1, 2022 Rs in Lai	
Particulars	Note	As At March 31, 2022	As At March 31, 2021
ASSETS			
Non-current wesets			
(a) Property, plant and equipment	э	1,332.92	1,819.1
(b) Capital Work-In Progress	3	53.39	-7 (1 a
(b) investment property	з	63.95	67.9
Financial essets			
(a) Loans & Advances	5	3.19	2.6
Other Non current assets	4		
Fatul Non - Current Assets		1,455.45	1,385.7
Current Assets			
nventories		100000000	1-0804
Inventuries Inancial assets	7	1,748.99	1,207.1
(A) investments			
(h) Trade receivables	0		
(c) Cash and cash equivalents	6 8	2,285.85	2,872.8
(d) Bank balances other than (c) above	8	4.44	3.5
(a) Other Current Financial Assets		2.10	2.1
Other current assets	10	137.61	4.4
fotel Current assets	1	4,189.07	332.4 3,602.5
lotal Assets		5,644.513	4,938.
EQUITY AND LIABILITIES			
hpulty		1	
quity share capital	11	875.38	874.3
Other equity	12	1,961.68	3,802.2
fotal Equity		2,836.06	2,676.8
Von-current Rabilities			
inancial Liabilities			
(a) Borrowings	13	248.26	
(b) Trade payables	10	248.28	375.2
Deferred tax liabilities, net	14	65.92	100
Provisions	15	206.38	67.6 208 3
Government Grants	13	200.30	36.9
fotal Non-current llabilities	1 1	522.56	688.0
urrent liabilities			
Inandai liabilities			
(a) Borrowings	16	12 440-712	-
(b) Trade payables	17	1,395.17	922.2
(c) Other Current financial liabilities	7.0	717.88	314.7
unert tax labilities, net	18		
The current liabilities	15	67.13	47.0
otal Current Robilities	19	2,285,90	339.5
'otal liabilities 'otal Equity and liabilities		2,808.45	2,311.65
and count and manuals		3,044.513	4,918.2
or Pundarikashyam And Associates	For a	nd on behiaf of the Boan	
Nartered Accountants		Concord Drugs Lin	hited
RN-0113305	S.N. no		
0/- //9/		7	5- Koni Rully
I.Surya Prakasa rao 🏼 🎼 🔄	1. Nagi Redidy		i Reddy Seelarn
artner	Managing Directo	ir Exe	cutive Director
The second se			
Ano-205125 tace: Hyderabatt	DIN 01764665		02829319

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Statement of Cash flow for the year ended 31st March .	2022		s in Lakins	_
Particulars	AG	and the second se	As at	
	Merch 3	1, 2022	March \$1, 2021	
A. CASH FLOW FROM OPERATING ACTIVITIES Profit Before Tax				
Adjustments for :	1 1	224,805		429.2
Profit on several Assets				
Depreciation and amortization supervise	176.45			
Finance costs	141.33			136.5
Interest income	11,231			124.5
Provision for Gratuty	11.63			10.8
	1 1	317		
Operating profit before working capital changes	-	541.35		689.4
Changes in searching applicat: (Refer Note 40)				50374
Adjustments for (increase) / decrease in operating assets				
Financial Assets				
Trade receivables	(213.04)	- 1	471.79	
Louns and Advances	(0.55)		50.98	
Differ Non Current assets	1.1		57.05	
Inventories	(561.83)		455.94	
Other Current assets	194.87		29.73	
Other tank balances			0.49	
Other Current financial Assets	(5.66)		10.291	
Adjustments for increase / (decrease) in operating Habilities:				
Trade payables	+03.11		(964.85)	
Borrowings Other current financial Babilities				
Other current inductor nationals	1.000			
Current tax babilities, net	-333.63		10000	
Provisions	20.06		35.16	
Deferred tas on amalgamation	-		(\$97.60)	
Cash generated from operations		144.54		300.0
Net income tan paid		2000000		208.6
Net cash flow from operating activities (A)	-	77.419	-	(47.0)
8. CASH FLOW FROM INVESTING ACTIVITIES		11.449		191.5
Capital expenditure on fixed asaets, including capital advances	-245.61		(367.40)	
(Refer Note (iii) below)	577185		Canal And	
Proceeds from maturity of fixed deposits				
- Others	1.23		0.81	
Vet cash (used in) / flow from investing activities (ti)		(244.186)		(366.5)
C. CASH FLOW FROM FINANCING ACTIVITIES		testorestant to		
Proceeds from issue of equity chares	1.04			
Finance costs	-141.33		[124.53]	
Repayment of Borrowings	-126.83		(22.42)	
Repayment of short term Barrowings	472.96		367.92	
Gost Sranta	-16.92		(8.61)	
Other equity Adjustment	-	0.000	-	
Net cash flow (used in) financing activities (C)	L L	167.861		207.36
Set (decompet in Cash and cash any) of one (2010)				
Vert (decrease) in Cash and cash equivalents (X+8+C) Cash and cash equivalents at the beginning of the year		0.89		2.34
Effect of exchange differences on translation of foreign		3.546		1.31
currency Cash and cash equivalents				141
(ash and cash equivalents at the end of the year (Refer Note (I) below)	11 II II	4.40		3.55
Comprises:		3.55		3.00
alonces with Banks		0.50		0.08
Others		3.94		3.46
		4.44		1.55
a per our report of even date		1004		1.20
or Pundarikashyam And Associates	For and on behal	f of the Board o	f Directors of	
	Concord Drugs Li			
hartered Accountants	and the second se			
	CIN. 124230T019	95#LC030093		
Him Registration No. 0113305	131		- parte	13.
Here Registration No. 0113305	CIN 2242301019		5. Kani L	sty
Here Registration No. 0113305	131	,	S' Komi Li ni Reddy Soeian	

Place: Hyderabod Date | 30.05.2022

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail : concorddrugsItd@gmail.com Website : www.concorddrugs.in

		The second se	ended 31st March '22	Rs in Lakhs
-	Particulars	Note	As at March 31,2022	As at March 31, 2021
1	Revenue from Operations		19120-552-1	
	a. Net sales from Operations	20	5,895.648	5,135.70
	Other Income	21	10.082	9.44
111	Total Revenue (I+II)		5,905.730	5,145.10
IV	Expenses		26/50/17/201-1	
	a.Cost of Material Consumed	22	4,441.147	4,049.1
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-231.057	168.6
	c. Employees Benefit Expenses	24	489.099	375.5
	d. Finance Costs	25	168.075	142.0
	e. Depreciation and Amortisation expense	3	176.451	135.5
	f. Other expenses	26	637.210	220.35
	Total Expenses		5,680.92	5,092.28
	Profit/ (Loss) before Exceptional item and tax (III-IV)		224.805	52.88
٧	Exceptional Items			376.3
VI	Profit/ (Loss) before tax (V+VI)		224.805	429.2
VII	Tax Expense:		65.3704	101.0
VIII	a. Current tax		67.1212	47.0
	b. Deferred tax charge/credit		+1.7508	53.96
IX	Profit/ (Loss) for the period (VII-VIII)		159.4347	328.17
х	Other Comprehensive Income			÷
	Items that will not be reclassified to profit or loss			
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period)		159.435	328.1
	(D(+X)			
XI	Paid-up equity share capital		874.375	874.38
	(Face value of the share- Rs. 10 each)			
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		1.82	3.75
	b. Diluted (in Rs)		1.82	3.75
	darikashyam and Associates		For and on behlaf of the Boa	ard of Directors of
	ed Accountants		Concord Drugs L	imited
3N-01	13305	B		
07-		18		
surya Prakasa Rao		SIN	en Rudly	5. Koni Reddy
artner		S. Nag	Reddy	Koni Reddy Seelam
no-20	5125	Manag	ting Director	Executive Director
		10000		DIN: 02829319

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To, BSE Limited, P.J. Towers, Dalal Street, Mumbai - 400001 Date: 30.05.2022

Dear Sir,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Nagi Reddy, Chairman & Whole time Director of Concord Drugs Limited hereby declare that the statutory Auditors of the company, M/s. Pundarikashyam and Associates, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2022.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely, For Concord Drugs Limited

5. Nogituty

S. Nagi Reddy Chairman & Whole time Director DIN: 01764665



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar, Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,

E-mail : info@pkas.in / infoong@pkas.in

GSTIN: 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12. 2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED,

- We have audited the accompanying statement of Standalone financial results of Concord Drugs Limited ('the company'), for the three months and year ended March 31,2022('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").
- 2. This statement is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing Regulations. Our responsibility is to express anopinion on the Statement based on our audit of such interim consolidated financial statement.
- 3. We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.



We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

- In our opinion and to the best of our information and according to the explanations given to us, the statement
 - is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - b gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2020.

For Pundarikashyam and Associates Chartered Accountants YAR FRN: 011330S Sents B. Sm ŝ HYDERABAD B.Surya Prakasa Rab (Partner) 20 400 MNo: 205125 UDIN: 22205125AJXVOC7149

Place: Hyderabad Date: 30.05.2022.